ABT-888 (Veliparib)

ABT-888 increases tumor growth delay in a NCI-H460 xenograft model. ABT-888 enhances the antitumor activity of temozolomide in the B16F10 and 9L xenograft models due to PARP inhibition.  ABT-888 exhibits good antitumor efficacy in MX-1 xenograft model in combination with other cytotoxic agents.  Combination with radiation, ABT-888 decreases the tumor vessel formation.  ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models.